Albireo Pharma Inc (ALBO) – Strategy, SWOT and Corporate Finance Report

Albireo Pharma Inc (ALBO) – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company

Key Highlights

Albireo Pharma Inc (Albireo), formerly Biodel Inc, It focuses on the development and commercialization of novel bile acid modulators for treatment of orphan pediatric liver diseases, gastrointestinal (GI) disorders and other diseases. Its pipeline products include odevixibat (A4250) intended for treatment of progressive familial intrahepatic cholestasis (PFIC), biliary atresia, alagille syndrome and other cholestaticc; A3384 for bile acid malabsorption; and elobixibat for nonalcoholic steatohepatitis (NASH). Elobixibat is approved in Japan for the treatment of chronic constipation. The company is investigating bile acid modulator for nonalcoholic steatohepatitis (NASH) and other preclinical trials for the treatment of adult liver diseases. It operates in the US, the UK, and Sweden. Albireo is headquartered in Boston, Massachusetts, the US.

Scope

• Detailed information on Albireo Pharma Inc required for business and competitor intelligence needs

• A study of the major internal and external factors affecting Albireo Pharma Inc in the form of a SWOT analysis

• An in-depth view of the business model of Albireo Pharma Inc including a breakdown and examination of key business segments

• News about Albireo Pharma Inc, such as business expansion, restructuring, and contract wins

• Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

• Track strategic initiatives of the company and latest corporate news and actions.

• Assess Albireo Pharma Inc as a prospective partner, vendor or supplier.

• Support sales activities by understanding your customers' businesses better.

• Stay up to date on Albireo Pharma Incs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Sandoz Inc

Shire Pharmaceuticals International UC

Par Pharmaceutical Holdings Inc

Mirum Pharmaceuticals Inc

GSK plc

Upsher-Smith Laboratories LLC

Shire Pharmaceuticals International UC

Sandoz Inc

GSK plc

Par Pharmaceutical Holdings Inc

Mirum Pharmaceuticals Inc

Upsher-Smith Laboratories LLC

Table of Contents